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Role of phospholipase A2 in the cytotoxic effects of oxalate in however, recent studies from our laboratory [2–6] and
cultured renal epithelial cells. those of others [7–9] demonstrated that oxalate exposure
Background. Oxalate, a common constituent of kidney elicits a variety of changes in renal epithelial cells, rang-stones, is cytotoxic for renal epithelial cells. Although the exact
ing from increased DNA synthesis and an induction ofmechanism of oxalate-induced cell death remains unclear, stud-
“immediate early genes” to increased membrane perme-ies in various cell types, including renal epithelial cells, have
implicated phospholipase A2 (PLA2) as a prominent mediator ability and cell death. The manner by which oxalate
of cellular injury. Thus, these studies examined the role of triggers these changes remains unclear. The observation
PLA2 in the cytotoxic effects of oxalate. that oxalate can increase free radical production in renalMethods. The release of [3H]-arachidonic acid (AA) or [3H]-
epithelial cells [5], coupled with the well-documentedoleic acid (OA) from prelabeled Madin-Darby canine kidney
role for free radicals as intracellular signals, suggests that(MDCK) cells was measured as an index for PLA2 activity.
The cell viability was assessed by the exclusion of ethidium superoxide or another reactive oxygen species (ROS)
homodimer-1. may mediate oxalate actions. Indeed, antioxidant agents
Results. Oxalate exposure (175 to 550 mm free) increased block both free radical generation and the changes inthe release of [3H]-AA in MDCK cells but had no effect on
cell viability produced by oxalate exposure [5].the release of [3H]-OA. Oxalate-induced [3H]-AA release was
Phospholipase A2 (PLA2) is a family of enzymes thatabolished by arachidonyl trifluoromethyl ketone (AACOCF3),
a selective inhibitor of cytosolic PLA2 (cPLA2), but was not hydrolyzes the acyl group from the sn-2 position of phos-
affected by selective inhibitors of secretory PLA2 and calcium- pholipids, generating free fatty acids such as arachidonic
independent PLA2. The [3H]-AA release could be demon- acid (AA) and lysophospholipids [10–13]. These en-strated within 15 minutes after exposure to oxalate, which is
zymes have also been implicated in the processes leadingconsiderably earlier than the observed changes in cell viability.
to cellular injury in many cell types [13–16], includingFurthermore, AACOCF3 significantly reduced oxalate toxicity
in MDCK cells. renal epithelial cells [17–20]. PLA2 activity may elicit
Conclusions. Oxalate increases AA release from MDCK direct effects on cellular function by perturbing mem-
cells by a process involving cPLA2. In addition, based on the brane phospholipids. Alternatively, PLA2 may indirectlyevidence obtained using a selective inhibitor of this isoform,
promote cell injury by the liberation of AA, a precursorit would appear that the activity of this enzyme is responsible,
for eicosanoids and other oxygenated metabolites. Suchat least in part, for the cytotoxic effects of oxalate. The finding
that oxalate can trigger a known lipid-signaling pathway may oxygenated metabolites can also act on the cell mem-
provide new insight into the initial events in the pathogenesis brane, influencing the activity of membrane channels
of nephrolithiasis. and/or proteins [10, 13]. These so-called lipid mediators
have also been implicated in various signal transduction
pathways leading to mitogenesis, differentiation, and in-
Oxalate, a common constituent of and a major risk flammation as well as cytotoxicity [10, 11, 21].
factor for kidney stones, is an end product of metabolism A number of structurally diverse forms of PLA2 havethat is excreted by the kidney [1]. This dicarboxylate had been identified, including 14 kDa secretory PLA2been considered to be an inert metabolic by-product; (sPLA2), 85 kDa cytosolic PLA2 (cPLA2), and calcium-
independent PLA2 (iPLA2) [12]. Of these, cPLA2 may
be of particular interest as a mediator of cell injury andKey words: MDCK cells, apoptosis, arachidonic acid, kidney stones,
cellular injury, nephrolithiasis. as an activator of intracellular signaling pathways [10,
11]. This form of PLA2 is active at physiological concen-Received for publication December 31, 1998
trations of Ca21 and preferentially hydrolyzes AA at theand in revised form March 10, 1999
Accepted for publication April 23, 1999 sn-2 position of phospholipids. Moreover, recent studies
by Sapirstein et al indicated that the overexpression of 1999 by the International Society of Nephrology
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cPLA2 in renal cells led to increased susceptibility to whereas N-acetylcysteine (NAC) was obtained from
Sigma Chemical. Fatty acid-free bovine serum albuminhydrogen peroxide-induced cytotoxicity, a finding that
suggests that this enzyme may play an important role (BSA) was purchased from Sigma Chemical.
in cellular processes leading to injury [17]. In contrast,
Cell culturesPLA2, an enzyme found in the extracellular fluid, has
no selectivity for sn-2 acyl group and requires millimolar Madin-Darby canine kidney cells (CCL 34, passages
53 to 90) were obtained from the American Type Cultureconcentrations of Ca21 for activation. The possible role
of iPLA2 is less clear; some investigators postulated that Collection (Rockville, MD, USA) and were maintained
in DMEM supplemented with 10% FBS, 4.5 g/literthis enzyme plays a role in cell injury [19], although no
definitive evidence has been provided. d-glucose and antibiotics (100 U/ml penicillin 1 100
mg/ml streptomycin) at 378C under 5% CO2/95% air. InInterestingly, studies in different systems have docu-
mented that ROS such as hydrogen peroxide [17, 22, 23] preparation for experiments, cells were plated in 12-well
culture plates and grown to 80% confluence. Becauseand superoxide [24] can promote the activation of cPLA2
with consequent release of AA. From the observation small differences in cell density and in cell passage num-
ber increased the variability of the cell responses, allthat oxalate can increase production of free radicals [5],
it follows that AA metabolism catalyzed by cPLA2 may experiments included matched controls, and data from
the various treatment groups were normalized to thebe involved in the mechanism by which oxalate elicits
renal cellular injury. To evaluate this hypothesis, we ex- data from these controls.
amined the effects of oxalate on AA release in Madin-
Measurement of arachidonic acid releaseDarby canine kidney (MDCK) cells and assessed the
effects of various antioxidants on AA release. Previous Subconfluent cultures of MDCK cells in 12-well plates
were incubated for 12 to 18 hours with 0.2 mCi/ml (2 tostudies on MDCK cells have demonstrated that these
cells express PLA2 activity [25–28] and exhibit sensitivity 3.3 nm) of [3H]-AA in serum-free DMEM. The cells were
then washed twice with phosphate-buffered saline (PBS,to oxalate toxicity [7–9]. Furthermore, these cells are
derived from distal tubules [29], the region of the neph- pH 7.4) and once with DMEM containing 0.2% fatty
acid-free BSA. During such labeling periods, cells incor-ron most likely to be exposed to toxic levels of oxalate
[30–32]. The results of these studies demonstrate that porated 94.0 6 0.5% of added radioactivity. The stimula-
tion of labeled cells with agents of interest was ordinarilyoxalate rapidly increase AA release from MDCK cells
by a process that appears to be mediated by cPLA2. conducted by incubation in 1 ml of DMEM containing
0.2% fatty acid-free BSA. BSA was included to minimizeMoreover, these studies suggest that this pathway may
play a role in the cytotoxic effects of oxalate. reacylation or metabolism of released fatty acids [33].
After varying periods of time, the medium was collected
and centrifuged to remove any floating cells, and the
METHODS
radioactivity in 400 ml of supernatant was measured in
Materials a liquid scintillation counter (LS 6500; Beckman Instru-
ments, Fullerton, CA, USA). Adherent cells were solubi-Dulbecco’s modified Eagle’s minimal essential me-
dium (DMEM) and antibiotics (penicillin/streptomycin) lized with 1 ml of 1% Triton X-100, and the radioactivity
in 400 ml of the cell lysate was determined. The releasewere obtained from GIBCO BRL (Grand Island, NY,
USA), fetal bovine serum (FBS) from Sigma Chemical of [3H]-AA into the medium was expressed as a percent-
age of total label incorporated (cell-associated plus re-(St. Louis, MO, USA). [5,6,8,9,11,12,14,15-3H(N)]-ara-
chidonic acid ([3H]-AA; 60 to 100 Ci/mmol) and [9,10- leased). In selected experiments, cells were labeled with
0.2 mCi/ml (20 to 100 nm) of [3H]-OA, and the release3H(N)]-oleic acid ([3H]-OA; 2 to 10 Ci/mmol) were ob-
tained from DuPont New England Nuclear (Cambridge, of [3H]-OA was assessed in the same manner.
MA, USA). Ethidium homodimer-1 was purchased from
Thin layer chromatography analysis of releasedMolecular Probes (Eugene, OR, USA). The PLA2 inhibi-
arachidonic acidtors mepacrine and dibucaine were obtained from Sigma
Chemical, whereas arachidonyl trifluoromethyl ketone The purity of the released [3H]-AA in the medium
was assessed using a modification of the thin layer chro-(AACOCF3), oleyloxyethyl phosphorylcholine (OPC),
haloenol lactone suicide substrate (HELSS), and the di- matography (TLC) methods described by Peters-Golden
and Feyssa [33]. The medium was extracted with twoacylglycerol (DAG) inhibitor 1,6-bis-(cyclohexyloximi-
nocarbonylamino)-hexane (RHC-80267) were obtained volumes of chloroform-methanol-acetic acid (100:50:1,
vol/vol/vol), and the organic phase was evaporated tofrom Biomol Research Laboratories (Plymouth, PA,
USA). The antioxidant Mn(III) tetrakis (4-benzoic acid) dryness under a stream of nitrogen. The residue was
dissolved in chloroform, applied to silica gel 60 platesporphyrin (MnTMPyP) was obtained from Calbiochem-
Novabiochem International (San Diego, CA, USA), (E. Merck, Darmstadt, Germany), and developed with
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hexane-diethyl ether-acetic acid (70:30:2, vol/vol/vol). analysis of variance was used, and a subsequent compari-
son among means was made using multiple t-tests withOne mm of unlabeled AA standard was added as a car-
rier, and the spot corresponding to AA (Rf 5 0.4) was a Bonferroni correction.
visualized with iodine vapors. Quantitative determina-
tions were obtained by scraping portions of the silica
RESULTS
gel into scintillation vials followed by liquid scintillation
Effect of oxalate on arachidonic acid release fromspectrometry. The results were expressed as a percentage
Madin-Darby canine kidney cellsof radioactivity in the fatty acid band relative to the total
radioactivity recovered from each lane. The exposure to oxalate produced a time- and concen-
tration-dependent release of [3H]-AA in MDCK cells
Experimental protocol (Fig. 1), with 1 mm oxalate (350 mm free oxalate) produc-
ing a twofold increase in [3H]-AA release within 15 min-Cells were exposed to oxalate and other agents by
exchanging media for DMEM containing 0.2% fatty utes (271 6 15% relative to control) and a sixfold in-
crease within 120 minutes (625 6 43% relative to control;acid-free BSA and the agents of interest, and continuing
the incubation at 378C under an atmosphere of 5% CO2/ Fig. 1A). The exposure to lower concentrations of oxa-
late produced lesser responses, but even 175 mm free95% air. Where indicated, sodium oxalate was added at
a concentration of 0.5, 1.0, and 1.5 mm (total), which oxalate significantly increased the [3H]-AA release
(321 6 62%) after 60 minutes (Fig. 1B). To determinecorresponded to free oxalate levels of 175, 350, and 550
mm and produced relative supersaturation levels (RSS) whether the released label reflected AA or other metab-
olites, the lipids in the medium were extracted after afor calcium oxalate of 12.9, 24.9, and 35.9, respectively.
Estimates of free oxalate and RSS were obtained using 60-minute exposure to 350 mm free oxalate and separated
using TLC. The result showed that approximately 80%the EQUIL program [34]. In the experiments testing the
effect of PLA2 inhibitors or DAG lipase inhibitors, the of the radioactivity in the medium was associated with
the free AA band on TLC plate.cells were preincubated for 10 minutes prior to oxalate
addition. For studies with the AACOCF3, cells were in-
Involvement of phospholipase A2 in arachidonic acidcubated in the absence of BSA. The effect of antioxidant
release from MDCK cellsagents on [3H]-AA release was also examined after a 60-
minute pretreatment. Liberation of AA from membrane phospholipids may
occur by at least two pathways. One is the direct release
Cell viability assay of AA from the sn-2 position of membrane phospholip-
ids by PLA2. The other is the cleavage of phosphoesterCell viability was assessed by the uptake of ethidium
homodimer-1, as described previously [5]. Briefly, sub- bonds by phospholipase C (PLC) to produce DAG, fol-
lowed by the degradation of DAG to AA by DAG lipaseconfluent cultures in 12-well plates were exposed to
graded concentrations of oxalate in serum-free DMEM [21]. To characterize the pathway that mediates AA re-
lease induced by oxalate, we assessed the effect of PLA2for varying periods. The medium was decanted, and each
well was stained for 20 minutes at 378C with 4 mm ethid- and DAG lipase inhibitors on [3H]-AA release. The re-
sults showed that pretreatment of MDCK cells with ei-ium homodimer-1, a fluorescent vital dye that is excluded
from intact cells [35]. Digital video images of three ran- ther 50 mm mepacrine or 50 mm dibucaine, two different
PLA2 inhibitors, reduced [3H]-AA release induced bydomly selected fields in each well were obtained using a
Zeiss inverted fluorescence microscope (Atto Industries, 550 mm free oxalate. Conversely, 20 mm RHC-80267,
which binds to the catalytic site of DAG lipase [36], wasRockville, MD, USA) with a filter set for ethidium
homodimer-1 (excitation l 525 nm and emission l 600 without effect (Fig. 2). Thus, oxalate-induced AA release
is mediated by a PLA2.nm). The number of dead cells in each image was deter-
mined by computer analysis using the NIH Image pro-
Specificity of sn-2 fatty acids released by oxalate ingram for Macintosh (National Institutes of Health,
MDCK cellsBethesda, MD, USA).
Because there are a number of isoforms of PLA2 in
Statistical analysis mammalian cells, including sPLA2, cPLA2, and iPLA2
[12], studies were performed to identify the PLA2 iso-The [3H]-AA release was quantitated as a fraction of
total [3H]-AA incorporated. [3H]-AA release data from form responsible for oxalate-induced AA release in
MDCK cells. Such studies took advantage of the estab-the various treatment groups were normalized relative to
control for each experiment. Student’s t-test for unpaired lished differences in acyl chain specificity among these
three forms of PLA2: cPLA2 preferentially hydrolyzesdata was used when only two unrelated treatment groups
were compared. To determine the statistical significance AA from sn-2 position of phospholipid, whereas sPLA2
and iPLA2 hydrolyze other fatty acyl esters in the sn-2of differences between more than two groups, one-way
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Fig. 2. Effect of phospholipase A2 (PLA2) inhibitors and diacylglycerol
(DAG) lipase inhibitor on oxalate-induced AA release from MDCK
cells. [3H]-AA–labeled MDCK cells were preincubated for 10 minutes
with 50 mm mepacrine, 50 mm dibucaine (PLA2 inhibitors), 20 mm RHC-
80267 (DAG lipase inhibitor), or corresponding vehicles followed by
an exposure for 60 minutes to 550 mm free oxalate. Inhibitors were also
included during incubation with oxalate. [3H]-AA release was deter-
mined as in Figure 1 and was expressed as a percentage of oxalate-
stimulated release in the absence of inhibitors. Stimulation of [3H]-AA
release by oxalate was counted as 100%. Oxalate-induced AA release
was inhibited by mepacrine and dibucaine, but not by RHC-80267. Data
are presented as means 6 se of at least three independent experiments
performed in triplicate; analysis employed multiple t-tests with a Bonfer-
roni correction to determine significance (*P , 0.0083).
position as well. Thus, we determined whether or not
oxalate would stimulate the release of [3H]-OA as well
as [3H]-AA from prelabeled cells. Figure 3 shows that
treatment of MDCK cells with 350 mm oxalate resulted
in a significant release of [3H]-AA but not of [3H]-OA.Fig. 1. Effect of oxalate on arachidonic acid (AA) release from Madin-
Darby canine kidney (MDCK) cells. (A) Time course. Subconfluent Conversely, melittin (1 mg/ml), a peptide that stimulates
cultures of MDCK cells were incubated for 12 to 18 hours with 0.2 mCi/
sPLA2 activity [22], increased both [3H]-AA and [3H]-ml (2 to 3.3 nm) of [3H]-AA in serum-free DMEM. After labeling, cells
were washed twice with PBS and once with DMEM containing 0.2% OA release. This finding implicates cPLA2 as the enzyme
fatty acid-free BSA. Cells were then exposed to 1 mm oxalate (350 mm primarily responsible for oxalate actions.free oxalate) in DMEM containing 0.2% fatty acid-free BSA at 378C.
At the times indicated (15, 30, 60, and 120 min), the medium was
collected, centrifuged, and counted for [3H]-AA released by cells, and Effect of selective inhibitors for different forms of
the adherent cells were solubilized with 1% Triton X-100 and counted phospholipase A2 on oxalate-induced arachidonic acidto determine [3H]-AA associated with cells. The release of [3H]-AA
into the medium was expressed as a percentage of the total incorporated release from MDCK cells
(cell-associated plus released). A significant increase in [3H]-AA release
To confirm the finding that cPLA2 might mediate oxa-was observed within 15 minutes after oxalate exposure, continuing
steadily for at least 120 minutes. The actual counts per minute (cpm) late-induced AA release in MDCK cells, the effects of
at 60 minutes were as follows: control (medium 540 6 31 cpm and cell selective PLA2 inhibitors were examined. As shown inlysate 31449 6 802 cpm); oxalate treatment (medium 3800 6 390 cpm
Figure 4A, the pretreatment of MDCK cells with AA-and cell lysate 27566 6 343 cpm). Therefore, the releases of [3H]-AA
for control and oxalate treatment were 1.7 6 0.1% and 12.0 6 1.1% COCF3, a selective inhibitor of human cPLA2 [37], mark-of total incorporated, respectively. Data are means 6 se of three inde-
edly inhibited [3H]-AA release stimulated with 550 mmpendent experiments performed in triplicate. *P , 0.01 using a Student’s
t-test. Symbols are: (m) control and (d) 350 mm free oxalate. (B) Con- oxalate. Moreover, this inhibition by AACOCF3 was
centration dependence. [3H]-AA–labeled cells were exposed for 60 concentration dependent, with a full blockade observedminutes at 378C to various concentrations of oxalate (0 to 550 mm free).
at a concentration of 5 mm (Fig. 4B). On the other hand,[3H]-AA release was determined as in panel A. Data are means 6
se of three independent experiments performed in triplicate; analysis OPC, a selective inhibitor for sPLA2 [38], and HELSS,employed multiple t-tests with a Bonferroni correction to determine
a selective inhibitor for iPLA2 [39], had no effect onsignificance (*P , 0.0083).
oxalate-induced [3H]-AA release (Fig. 4A). These results
indicated that the form of PLA2 that mediated oxalate-
induced AA release in MDCK cells was indeed a cPLA2.
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Fig. 3. Release of [3H]arachidonic acid (AA; ) or oleic acid (OA;
) from MDCK cells treated with oxalate and melittin. Subconfluent
cultures of MDCK cells were incubated for 18 hours with 0.2 mCi/ml
of [3H]-AA (2 to 3.3 nm) or [3H]-OA (20 to 100 nm) in serum-free
DMEM. After washing, the cells were exposed for 60 minutes at 378C
to 350 mm oxalate or 1 mg/ml of melittin, a peptide which stimulates
sPLA2 activity. Fatty acid release was determined as in Figure 1 and
was expressed as a percentage of corresponding controls (untreated).
Oxalate exposure resulted in significant release of [3H]-AA but not of
[3H]-OA, whereas melittin increased both [3H]-AA and [3H]-OA re-
lease. Data are means 6 se of four independent experiments performed
in triplicate; an analysis employed multiple t-tests with a Bonferroni
correction to determine significance. *P , 0.0167.
Effect of free radicals on arachidonic acid release
from MDCK cells
Our previous studies have demonstrated that oxalate
toxicity in renal epithelial cell lines may be mediated by
free radical production [5]. Because ROS can activate
Fig. 4. Effect of selective inhibitors for different forms of phospholi-PLA2 and increase AA release [17, 22–24], it is possible
pase A2 (PLA2) on oxalate-induced [3H]arachidonic acid (AA) releasethat the oxalate-induced increase in AA release may be from MDCK cells. (A) Effect of arachidonyl trifluoromethyl ketone
secondary to the production of free radicals. To assess (AACOCF3, cPLA2 inhibitor), oleyloxyethyl phosphorylcholine (OPC,
sPLA2 inhibitor), and haloenol lactone suicide substrate (HELSS, iPLA2this possibility, the effects of oxalate on AA release with
inhibitor). [3H]-AA–labeled MDCK cells were preincubated for 10 min-the effects of hydrogen peroxide and superoxide were
utes with 10 mm AACOCF3, 20 mm OPC, 10 mm HELSS, or correspond-compared. As shown in Figure 5, the exposure of MDCK ing vehicles followed by exposure for 60 minutes to 550 mm oxalate.
Inhibitors were also included during incubation with oxalate. [3H]-AAcells to 1.5 mm hydrogen peroxide increased [3H]-AA
release was determined as in Figure 1 and was expressed as a percentagerelease by 261 6 15%. Similarly, the generation of super-
of oxalate-stimulated release in the absence of inhibitors. The stimula-oxide by incubation with 1 mm xanthine 1 100 mU/ml tion of [3H]-AA release by oxalate was counted as 100%. Oxalate-
xanthine oxidase increased [3H]-AA release by 186 6 induced [3H]-AA release was inhibited by AACOCF3, whereas neither
OPC nor HELSS blocked the response. Data are presented as means 69%. Unlike oxalate, however, the effects of hydrogen
se of at least three independent experiments performed in triplicate;peroxide or superoxide were not inhibited by the pre- analysis employed multiple t-tests with a Bonferroni correction to deter-
treatment of 5 mm AACOCF3. mine significance. *P , 0.0083. (B) Concentration dependency of AA-
COCF3. Experiments were carried out as in (A). [3H]-AA release wasTo further define the relationship between oxalate-
expressed as a percentage of controls (untreated). The inhibitory effectinduced AA release and the production of free radicals,
of AACOCF3 was concentration-dependent such that 5 mm of AA-we examined effects of antioxidants [MnTMPyP (500 COCF3 abolished oxalate-induced [3H]-AA release. Data are means 6
mm), a superoxide dismutase mimic, and NAC (20 mm), a se of three independent experiments performed in triplicate; analysis
employed multiple t-tests with a Bonferroni correction to determineglutathione precursor], which have been shown to inhibit
significance (*P , 0.005).oxalate-induced cytotoxicity. In the presence of these
agents, however, basal and oxalate-induced [3H]-AA re-
leases were still apparent (Fig. 6).
Role of arachidonic acid release in oxalate-induced tures of MDCK cells were labeled with [3H]-AA and
cell toxicity were simultaneously exposed to graded concentrations
of oxalate. At different time intervals, cell viability wasNext, the relationship between oxalate-induced AA
release and cytotoxicity was examined. Replicate cul- measured in one replicate and [3H]-AA release in the
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Fig. 5. Effect of arachidonyl trifluoromethyl keytone (AACOCF3) on Fig. 6. Effect of antioxidants on oxalate-induced AA release from
oxalate-, hydrogen peroxide-, and xanthine/xanthine oxidase (XO)- MDCK cells. [3H]-AA–labeled MDCK cells were preincubated for 60
induced [3H]arachidonic acid (AA) release in MDCK cells. [3H]-AA– minutes with 500 mm MnTMPyP, 20 mm NAC, or corresponding vehicles
labeled MDCK cells were preincubated for 10 minutes with 5 mm AA- followed by exposure for 60 minutes to 350 mm oxalate ( ). Inhibitors
COCF3 ( ) or corresponding vehicles (h) followed by exposure for were also included during incubation with oxalate. [3H]-AA release was
60 minutes to 350 mm oxalate, 1.5 mm hydrogen peroxide, or 1 mm determined as in Figure 1 and was expressed as a percentage of control
xanthine 1 100 mU/ml XO. Inhibitors were also included during incuba- (untreated; h). Neither MnTMPyP nor NAC affected basal release of
tion with these stimuli. [3H]-AA release was determined as in Figure [3H]-AA or oxalate-induced release. Data are presented as means 6 se
1 and was expressed as a percentage of controls (untreated). Unlike of three independent experiments performed in triplicate; no significant
oxalate, [3H]-AA release induced by hydrogen peroxide or xanthine 1 difference was detected using analysis of variance.
XO was not inhibited by AACOCF3. Data are means 6 se of three
independent experiments performed in triplicate. *P , 0.01 vs. corre-
sponding vehicles using Student’s t-test.
results from the activity of the species of lipase termed
PLA2. Although deacylation of AA can also be catalyzed
other. Oxalate-induced [3H]-AA release occurred prior by the sequential actions of PLC and DAG lipase [21],
to changes in cell viability, as measured by ethidium two pieces of evidence argued against the involvement
homodimer-1 uptake. The concentration dependence of of this pathway in the response to oxalate. First, RHC-
both processes was quite similar (Fig. 7). 80267, a specific inhibitor of DAG lipase [36], failed to
To obtain further evidence that cPLA2-mediated AA block oxalate-induced [3H]-AA release, whereas mepa-
release might contribute to oxalate toxicity, we examined crine and dibucaine, two general PLA2 inhibitors, attenu-
the effect of AACOCF3 on oxalate-induced cell death. ated the response. Second, TLC analysis failed to detect
As shown in Table 1, the pretreatment of MDCK cells significant production of DAG after oxalate exposure.
with 1 and 5 mm AACOCF3, concentrations that block Indeed, PLA2 is generally thought to be the major acylhy-
[3H]-AA release, produced a significant decrease in the drolase responsible for liberation of AA [21], and the
number of cells killed by exposure to 350 mm oxalate. previously mentioned results support the involvement
This inhibitor also blocked the effects of A23187, a diva- of this enzyme in the increased AA release by oxalate
lent cation ionophore that stimulates cPLA2 activity in exposure.
MDCK cells [25, 26], on [3H]-AA release and on the Many different forms of mammalian PLA2 have been
death of renal cells. Cells were pretreated with AACOCF3 identified, and the form of PLA2 involved varies forand were then exposed to 5 mm A23187. As can be seen different cell types, stimuli, and pathophysiological pro-
in Table 1, ionophore alone significantly increased [3H]- cesses [12]. However, available evidence from our studies
AA release and cell death; pretreatment with the cPLA2 implicates the cytosolic form of PLA2 as the isoforminhibitor blocked both responses.
catalyzing oxalate-induced AA release. First, the enzyme
showed specificity for AA at the sn-2 position in that
DISCUSSION oxalate treatment failed to liberate [3H]-OA from prela-
beled cells under conditions in which [3H]-AA releaseThese studies are, to our knowledge, the first to dem-
was apparent. Other forms of PLA2 such as sPLA2 andonstrate that oxalate directly affects lipid metabolism in
iPLA2 reportedly fail to show this selectivity [10]. Therenal epithelial cells. Moreover, these studies provide the
specificity for AA in oxalate treatment is in markedcompelling evidence that this change in lipid metabolism
contrast to the effect of melittin, a sPLA2-activating pep-plays an important role in oxalate-induced cytotoxicity.
tide that is also known to perturb cell membranes (pro-Oxalate exposure produced a rapid increase in the re-
ducing pore formation and cytolysis) [40], which releaseslease of [3H]-AA in MDCK cells. Several findings indi-
cate that oxalate-induced AA release in MDCK cells both [3H]-OA and [3H]-AA from MDCK cells. Second,
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Table 1. Effect of AACOCF3 on oxalate- and A23187-induced
changes in AA release and cell viability
[3H]AA releasea Cell deathb
Treatment % control number/field
Oxalate 1
Vehicle 572.6647.5 128.7 69.1
AACOCF3 1 mm 189.5614.3c 87.867.2c
AACOCF3 5 mm 124.9615.4c 78.5610.6c
A23187 1
Vehicle 1347.2632.2 68.3 613.0
AACOCF3 1 mm ND 57.469.8
AACOCF3 5 mm 370.7620.0c 20.164.3c
Abbreviations are in the Appendix. Data are presented as means 6 se of 3
independent experiments performed in triplicate. ND is not determined.
a [3H]AA-labeled MDCK cells were pre-incubated for 10 min with 1 or 5 mm
AACOCF3 or corresponding vehicles followed by exposure for 60 min to 550
mm oxalate or 5 mm A23187. Inhibitors were also included during incubation
with oxalate. [3H]AA release was determined as in Fig. 1 and expressed as a
percentage of control (untreated).
b Subconfluent cultures of MDCK cells were serum starved for 18 hours before
experiment. Cells were pre-incubated for 30 min with 1 or 5 mm AACOCF3 or
corresponding vehicles followed by exposure for 120 min to 350 mm oxalate or
5 mm A23187. Cell viability was assessed as in Fig. 7B.
cAnalysis employed multiple t-tests with a Bonferroni correction to determine
significance; hence, *P , 0.0167 vs. corresponding vehicle.
cPLA2 as the enzyme primarily responsible for oxalate-
induced AA release from MDCK cells, although we can-
not entirely rule out a contribution from other forms of
PLA2, given the limited selectivity and efficacy of the
pharmacological tools available. Our findings are consis-
tent with those of others who found that cPLA2 mediates
Fig. 7. Effect of oxalate on AA release and cell death in MDCK cells. AA release in response to several agonists in this cell
Replicate cultures of MDCK cells were prepared. One replicate was line [25–28].
incubated for 18 hours in serum-free DMEM containing 0.2 mCi/ml
The mechanisms by which oxalate elicits cPLA2-medi-[3H]-AA and the other in serum-free DMEM. Both cultures were then
treated with graded concentrations of oxalate (0, 350, and 550 mm) ated AA release in MDCK cells are currently unknown.
simultaneously. At different time intervals, the [3H]-AA release was Other agents that increase AA release via this pathway
measured in one replicate and cell viability in the other. (A) [3H]-AA
appear to do so by activating the enzyme. cPLA2 can berelease. [3H]-AA release was determined as in Figure 1 and was ex-
pressed as a percentage of total incorporated. (B) Cell viability. Cell activated by an increase in cytosolic Ca21, which in turn
viability was assessed by staining for 20 minutes at 378C with 4 mm promotes translocation and binding of the enzyme to
ethidium homodimer-1, a fluorescent vital dye that stains only dead
the membrane phospholipid substrate and/or by phos-cells. Digital video images of three randomly selected fields in each
well were obtained using a inverted fluorescence microscope with a phorylation via stimulus-activated kinases [10, 11]. How-
filter set: excitation l 525 nm, emission l 600 nm. The number of dead ever, previous studies failed to demonstrate oxalate-cells in each image was determined by computer analysis. Note that
induced increases in intracellular Ca21 [42]. On the other350 mm oxalate produced an apparent increase in [3H]-AA release at
60 minutes when no significant difference was observed in the number hand, although the precise mechanisms leading to phos-
of dead cells. Furthermore, the concentration of oxalate that affected phorylation of the enzyme remain unclear, some haveboth processes was quite similar. Data are presented as means 6 se of
shown that ROS can promote phosphorylation of cPLA2at least three independent experiments performed in triplicate; analysis
employed multiple t-tests with a Bonferroni correction to determine [22, 23, 43]. Because oxalate produces ROS in renal
significance (*P , 0.0083). Symbols are: (h) control; ( ) 350 mm oxa- epithelial cells [5], it is possible that oxalate-induced AAlate; ( ) 550 mm oxalate.
release in MDCK cells is secondary to the generation of
ROS. However, two antioxidants, NAC and MnTMPyP,
which inhibit oxalate-induced cytotoxicity, failed to
block oxalate-induced [3H]-AA release. Furthermore,oxalate-induced [3H]-AA release was abolished by
[3H]-AA release in response to exogenous radicals wasAACOCF3, a relatively selective inhibitor for cPLA2
not inhibited by AACOCF3. These results suggest that[37]. (Note, however, that this compound also inhibits
intracellular ROS generation may not be a cause of AAiPLA2 in other cell lines [41].) Finally, neither OPC, a
release; rather, it may be a consequence of cPLA2-medi-selective inhibitor for sPLA2 [38], nor HELSS, a selective
inhibitor for iPLA2 [39], blocked oxalate-induced [3H]- ated AA release, possibly because of the subsequent
conversion of released AA to oxidized metabolites.AA release. These findings strongly support the role of
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Another potential mechanism that may participate in PK1 cells are quite sensitive to oxalate toxicity [4, 5],
even though this cell line expresses relatively low levelsincreased AA release during oxalate exposure is some
of cPLA2 [17]. Recently, a novel family of iPLA2 hassort of alteration in membrane phospholipid substrate.
been cloned from rabbit kidney and proposed to mediateFor example, in vitro experiments have demonstrated
hypoxic/ischemic cell injury [9, 53, 54]. Because the cata-that peroxidized lipid substrates are susceptible to hydro-
lytic activity of this enzyme is specific for sn-2 AA andlysis by PLA2, probably because of conformational
its responses to AACOCF3 or HELSS are still unknown,changes in the substrate [44–46]. A recent study by
we currently cannot rule out the possible involvementThamilselvan and Khan demonstrated that oxalate expo-
of this novel iPLA2 in oxalate-induced cytotoxicity. How-sure elicits lipid peroxidation in MDCK cells [9]. More-
ever, based on the evidence obtained using AACOCF3, aover, augmented AA release in response to lipid peroxi-
selective inhibitor for cPLA2, it is reasonable to concludedation has been reported in several cell lines [47, 48],
that the cytotoxic effect of oxalate is dependent, at leastincluding renal epithelial cells [18]. Thus, it is possible
in part, on well-characterized cPLA2 activity.that oxalate-induced lipid peroxidation might account
The exact mechanism by which cPLA2 could mediatefor our results. Note, however, that we failed to observe
oxalate toxicity in MDCK cells remains to be deter-changes in the chromatographic profile of released lipids
mined. We considered the possibility that the liberatedthat would be expected with peroxidation.
AA and/or metabolites might lead to cell injury, butOn the other hand, lipocortins, Ca21-, and phospho-
exogenous AA had no effect on the viability of MDCKlipid-binding proteins, also called annexins, have been
cells (data not shown). Furthermore, Alkhunaizi et alfound to inhibit PLA2-mediated hydrolysis of AA, prob-
have recently shown that exogenous AA protects againstably by binding to phospholipid in a Ca21-dependent
hypoxic injury in rat proximal tubules, perhaps becausemanner and therefore sequestering substrates from the
of a negative feedback inhibition of PLA2 activity [55].enzyme [49, 50]. It is possible that oxalate might modu-
On the other hand, oxalate toxicity may be mediatedlate this process by competing with lipocortins for the
by increased generation of lysophospholipids, anotherbinding to membrane phospholipid, thus changing acces-
product of cPLA2. Studies in other cell types have sug-sibility of the enzyme. Previous studies have shown that
gested a role for lysophospholipids in mediating celloxalate in the form of calcium oxalate monohydrate crys-
membrane disruption and cytotoxicity [56]. It is alsotals binds to anionic sites on the surface of renal epithelial
possible that cPLA2 activity leads to the formation ofcells [51, 52]. Moreover, this binding can be blocked by
ceramide, a known component of diverse cellular re-annexin V [52]. Further studies are required to define
sponses to stress, including cell death [57, 58]. In thiswhich of these mechanisms may participate in the aug-
regard, our recent studies have revealed oxalate-induced
mented AA release in response to oxalate. generation of ceramide in MDCK cells (Dr. Cao, unpub-
A central role for cPLA2 has been proposed in the lished observations).
cytotoxic effects of a variety of insults ranging from free These studies have demonstrated that oxalate can in-
radicals [14, 17, 18] to cytokines [15, 16] and ischemia [19, duce cPLA2-mediated AA release and produce damage20]. We have demonstrated that the enzymatic activity of to renal epithelial cells. Whether or not a similar process
cPLA2 is responsible for the oxalate-induced cytotoxicity occurs in vivo and whether this process contributes to the
in MDCK cells, a conclusion supported by the following development of stone disease remain unclear. However,
findings. First, treatment of MDCK cells with oxalate hyperoxaluria produces damage to renal tubular cells in
resulted in [3H]-AA release by a process that appears vivo, as evidenced by enzymuria and membranuria [59],
to involve cPLA2. Second, the liberation of [3H]-AA and oxalate exposure in vitro promotes the adherence
preceded oxalate-induced changes in cell viability as- of calcium oxalate crystals to renal epithelial cells by a
sessed by dye exclusion. Third, both [3H]-AA release mechanism involving membrane phospholipids (Dr.
and cell death by oxalate exposure showed a similar Cao, unpublished observation; Dr. Mandel, personal
concentration dependency. Finally, and most impor- communication). In addition, studies by Baggio et al
tantly, the treatment of MDCK cells with AACOCF3 have demonstrated that human stone formers show alter-
attenuated oxalate-induced cell death. Furthermore, nations in arachidonate metabolism [60], suggesting the
A23187, which has been shown to activate cPLA2 in important role of lipid metabolism in this disease. Thus,
MDCK cells [25, 26], mimicked the cytotoxic effect of additional insights as to the cellular consequences of
oxalate. Moreover, the cytotoxic effect of A23187 was oxalate-induced changes in phospholipid metabolism
also blocked by AACOCF3. Despite its ability to abolish may prove useful in understanding the pathogenesis of
AA release, AACOCF3 did not completely inhibit oxa- kidney stone disease.
late-induced cell death, which may suggest the existence
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